AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
SIGA Technologies, Inc.
Video analysis: SIGA
All videosNo video analysis for this stock yet. Request one from our team.
News: SIGA
Dimensional Fund Advisors LP Grows Stock Holdings in Siga Technologies Inc. $SIGA
Dimensional Fund Advisors LP grew its position in Siga Technologies Inc. (NASDAQ: SIGA) by 6.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,702,724 shares of the company's stock after buying an additional 165,930 shares during the quarter. Dimensional
SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript
SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript
Siga Technologies Q2 Earnings Call Highlights
Siga Technologies NASDAQ: SIGA reported second-quarter product-related revenue of $38 million, driven primarily by deliveries of intravenous TPOXX to the U.S. Strategic National Stockpile and oral TPOXX sales to international customers. The company said the quarter reflected the variable timing of its government-focused procurement business after minimal product revenue in the first quarter.
SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must
Siga Technologies, Inc. remains a Hold, as revenue visibility hinges on BARDA contract renewal, with shares down ~40% since April. SIGA's sole commercial product, TPOXX, faces shrinking opportunities after losing EU approval for MPOX although mgmt is developing pediatric and PEP versions. Q1 2026 results showed stagnant revenues, widening losses, and reliance on a $26m BARDA delivery and $13m Asia Pacific contract.
